Member Type: Emerging Biotech/Pharmaceutical Companies
Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. The company's transformative product candidates are adoptive cell therapies and bispecific TCR molecules. These products are directed against tumor targets that have been identified and validated by Immatics' proprietary XPRESIDENT® technology. The company's mission is to bring the power of T-cell redirecting immunotherapies to cancer patients.